Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax, Inc. (Nasdaq: NVAX) has appointed Dr. Madelyn 'Lyn' Caltabiano as Senior Vice President of Global Program Management, a newly created role aimed at enhancing their vaccine development efforts. Dr. Caltabiano, who has extensive experience in managing global programs, will lead strategies to assess operational performance related to Novavax's vaccine pipeline. Her previous roles included leadership positions at NexEos Diagnostics and Merck. The company continues to advance its COVID-19 vaccine candidate, NVX-CoV2373, currently undergoing pivotal trials in the U.K. and the U.S.
Novavax, a late-stage biotechnology company, has appointed Henrietta Ukwu, M.D., as Senior Vice President, Chief Regulatory and Quality Officer. Dr. Ukwu will oversee global regulatory strategy and quality assurance for Novavax's vaccine candidates, including NVX-CoV2373, aimed at combating COVID-19. With extensive experience in regulatory affairs from previous roles at Otsuka Pharmaceuticals, PPD, and Merck, she is expected to significantly contribute to Novavax’s advancements in vaccine development.
Novavax has signed an Advance Purchase Agreement with Australia for 51 million doses of its COVID-19 vaccine NVX-CoV2373. Initial deliveries are anticipated by mid-2021, pending regulatory approval. This agreement follows a preliminary deal made in November 2020 and allows Australia an option for an additional 10 million doses.
Currently, Novavax is conducting late-stage clinical trials in the U.S., Mexico, and the U.K. to validate the vaccine's efficacy and safety, bolstered by its proprietary adjuvant Matrix-M™.
On January 6, 2021, Novavax (Nasdaq: NVAX) announced participation in two investor conferences, focusing on its COVID-19 vaccine candidate, NVX-CoV2373. The J.P. Morgan Healthcare Conference will take place on January 11, 2021, featuring presentations by key executives, including CEO Stanley C. Erck. Additionally, the 13th Annual Biotech Showcase is scheduled for January 8, 2021, with a panel discussing Novavax's journey during the pandemic. NVX-CoV2373, a protein-based vaccine, has shown promising results in clinical trials and is currently in pivotal Phase 3 evaluations.
Novavax initiated PREVENT-19, a pivotal Phase 3 trial in the U.S. and Mexico to assess the efficacy and safety of NVX-CoV2373, its COVID-19 vaccine candidate. The study aims to enroll up to 30,000 participants, with two-thirds receiving the vaccine and one-third a placebo. Previous Phase 1/2 trials demonstrated a robust immune response. Supported by Operation Warp Speed, this trial is critical for developing vaccines to combat the pandemic. Results from this and other ongoing studies are expected soon, potentially influencing vaccine availability.
Novavax (Nasdaq: NVAX) announced the appointment of Rick Crowley as Executive Vice President, Chief Operations Officer. Crowley will oversee all operations, including Quality, Manufacturing, Supply Chain, and Regulatory Affairs, taking over from Ben Machielse, who will remain as an executive advisor. Crowley brings extensive experience in biopharmaceuticals, having previously held senior roles at TerSera and Crealta. Novavax aims to leverage Crowley's expertise to enhance its manufacturing capabilities and advance its COVID-19 and influenza vaccine candidates.
Novavax, Inc. (Nasdaq: NVAX) has entered into an Advance Purchase Agreement with the New Zealand government for 10.7 million doses of its COVID-19 vaccine candidate, NVX-CoV2373. The vaccine, currently in Phase 3 clinical trials in the UK, utilizes Novavax's proprietary Matrix-M™ adjuvant to boost immune response. Initial deliveries are targeted for mid-2021, pending regulatory approvals. Novavax aims to ensure vaccine accessibility for New Zealanders, reflecting confidence in its candidate amid the ongoing pandemic.
Novavax, Inc. (Nasdaq: NVAX) has appointed Margaret G. McGlynn, R. Ph., as an independent director on its board. McGlynn brings significant experience in vaccine commercialization and public health, which will be crucial as Novavax approaches the Phase 3 data collection for its COVID-19 vaccine candidate, NVX-CoV2373. With a strong background from the International AIDS Vaccine Initiative and Merck, she aims to bolster Novavax's mission to distribute the vaccine globally. Currently, Novavax is also advancing its quadrivalent influenza nanoparticle vaccine.
Novavax, Inc. (Nasdaq: NVAX) has announced significant progress in its COVID-19 vaccine program, NVX-CoV2373. The pivotal Phase 3 trial in the U.K. is fully enrolled with 15,000 participants, while the Phase 2b trial in South Africa has also completed enrollment with 4,422 participants. A Phase 3 trial in the U.S. and Mexico is set to commence soon. The company has garnered $1.6 billion in funding from the U.S. government and anticipates interim data from these trials in early 2021, potentially supporting global regulatory applications.
Novavax (Nasdaq: NVAX) announced participation in two investor conferences to discuss its COVID-19 vaccine candidate, NVX-CoV2373. The first is the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, featuring a panel discussion moderated by Edward A. Tenthoff and Yasmeen Rahimi, with Dr. Gregory M. Glenn as a panelist. The second event is the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, which includes a fireside chat and investor meetings. NVX-CoV2373 is currently in various stages of clinical trials and has secured $2 billion in funding for its vaccine program.